Base de dados : MEDLINE
Pesquisa : D27.505.696.560.374 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27558168
[Au] Autor:Abu Farha R; Bustanji Y; Al-Hiari Y; Al-Qirim T; Abu Shiekha G; Albashiti R
[Ad] Endereço:a Faculty of Pharmacy , The University of Jordan , Amman , Jordan and.
[Ti] Título:Lipid lowering activity of novel N-(benzoylphenyl)pyridine-3-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats.
[So] Source:J Enzyme Inhib Med Chem;31(sup4):138-144, 2016.
[Is] ISSN:1475-6374
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Dyslipidemia is a major risk factor for the development of cardiovascular diseases. Many dyslipidemic patients do not achieve their target lipid levels with the currently available medications, and most of them may experience many side effects. OBJECTIVE: The present work aimed toward identifying a new class of novel nicotinic acid-carboxamide derivatives as promising antihyperlipidemic compounds. MATERIALS AND METHODS: Six novel N-(benzoylphenyl)pyridine-3-carboxamide derivatives were synthesized using acid chloride pathways. All structures were confirmed using H-NMR, C-NMR, IR, and HRMS. The evaluation of biological activity was conducted using Triton WR-1339-induced hyperlipidemic rats model. RESULTS: This study revealed that some of the newly synthesized novel N-(benzoylphenyl)pyridine-3-carboxamide derivatives mainly C4 and C6 possessed significant antihyperlipidemic activities on lipid components TG and TC (p value <0.05). DISCUSSION AND CONCLUSION: This research opens the door for new potential antihyperlipidemic compounds derived from nicotinic acid that need further optimization of their biological activities.
[Mh] Termos MeSH primário: Anti-Hipercalêmicos/farmacologia
Hiperlipidemias/induzido quimicamente
Hiperlipidemias/tratamento farmacológico
Lipídeos/antagonistas & inibidores
Polietilenoglicóis
Piridinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Anti-Hipercalêmicos/síntese química
Anti-Hipercalêmicos/química
Modelos Animais de Doenças
Lipídeos/sangue
Masculino
Estrutura Molecular
Piridinas/síntese química
Piridinas/química
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihyperkalemic Agents); 0 (Lipids); 0 (N-(benzoylphenyl)pyridine-3-carboxamide); 0 (Pyridines); 30IQX730WE (Polyethylene Glycols); Y27PUL9H56 (tyloxapol)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170222
[Lr] Data última revisão:
170222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160826
[St] Status:MEDLINE


  2 / 2 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26912544
[Au] Autor:Whittle J; Lynch AI; Tanner RM; Simpson LM; Davis BR; Rahman M; Whelton PK; Oparil S; Muntner P
[Ad] Endereço:Primary Care Division, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; jeffrey.whittle@va.gov.
[Ti] Título:Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
[So] Source:Clin J Am Soc Nephrol;11(3):471-80, 2016 Mar 07.
[Is] ISSN:1555-905X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: Increased visit-to-visit variability of BP is associated with cardiovascular disease risk. We examined the association of visit-to-visit variability of BP with renal outcomes among 21,245 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured mean BP and visit-to-visit variability of BP, defined as SD, across five to seven visits occurring 6-28 months after participants were randomized to chlorthalidone, amlodipine, or lisinopril. The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization. We repeated the analyses using average real variability and peak value of systolic BP and for visit-to-visit variability of diastolic BP. RESULTS: Over a mean follow-up of 3.5 years, 297 outcomes occurred. After multivariable adjustment, including baseline eGFR and mean systolic BP, the hazard ratios for the composite end point were 1.29 (95% confidence interval [95% CI], 0.75 to 2.22), 1.76 (95% CI, 1.06 to 2.91), 1.46 (95% CI, 0.88 to 2.45), and 2.05 (95% CI, 1.25 to 3.36) for the second through fifth (SD of systolic BP =6.63-8.82, 8.83-11.14, 11.15-14.56, and >14.56 mmHg, respectively) versus the first (SD of systolic BP <6.63 mmHg) quintile of SD of systolic BP, respectively (P trend =0.004). The association was similar when ESRD and a 50% decline in eGFR were analyzed separately, for other measures of visit-to-visit variability of systolic BP, and for visit-to-visit variability of diastolic BP. CONCLUSIONS: Higher visit-to-visit variability of BP is associated with higher risk of renal outcomes independent of mean BP.
[Mh] Termos MeSH primário: Pressão Sanguínea
Taxa de Filtração Glomerular
Hipertensão/complicações
Hipertensão/fisiopatologia
Rim/fisiopatologia
Insuficiência Renal Crônica/etiologia
Insuficiência Renal Crônica/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Anlodipino/uso terapêutico
Anti-Hipercalêmicos/uso terapêutico
Pressão Sanguínea/efeitos dos fármacos
Determinação da Pressão Arterial
Clortalidona/uso terapêutico
Progressão da Doença
Feminino
Seres Humanos
Hipertensão/diagnóstico
Hipertensão/tratamento farmacológico
Falência Renal Crônica/etiologia
Falência Renal Crônica/fisiopatologia
Lisinopril/uso terapêutico
Masculino
Meia-Idade
Análise Multivariada
Valor Preditivo dos Testes
Modelos de Riscos Proporcionais
Ensaios Clínicos Controlados Aleatórios como Assunto
Insuficiência Renal Crônica/diagnóstico
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antihyperkalemic Agents); 1J444QC288 (Amlodipine); E7199S1YWR (Lisinopril); Q0MQD1073Q (Chlorthalidone)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170307
[Lr] Data última revisão:
170307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160226
[St] Status:MEDLINE
[do] DOI:10.2215/CJN.04660415



página 1 de 1
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde